Novartis Gene Therapy: 5 Essential Strategies from SVP Joshi Venugopal

“Europe has roughly double the population of the United States but lower pricing, so it’s a balancing act between how much volume can you get and how little price discount you give.” – Joshi Venugopal

Joshi Venugopal, Head of Region Europe for Novartis Gene Therapy & Rare Diseases and Senior Vice President, brings extensive experience spanning R&D, early pipeline development, and in-market commercialisation.

Ahead of his keynote at CDMO Live, Joshi shares valuable insights on how to successfully commercialise gene therapies in Europe, including innovative pricing models and critical success factors. His strategic approach offers essential guidance for biotechs and pharmaceutical companies looking to navigate the complex European landscape.

Read the full interview